參考文獻 |
Reference
1. Reya, T., et al., Stem cells, cancer, and cancer stem cells. Nature, 2001. 414(6859): p. 105-111.
2. Verfaillie, C.M., M.F. Pera, and P.M. Lansdorp, Stem cells: hype and reality. Hematology Am Soc Hematol Educ Program, 2002: p. 369-91.
3. Guo, W., J.L. Lasky, and H. Wu, Cancer Stem Cells. Pediatric Research, 2006. 59: p. 59R-64R.
4. Morrison, S.J. and I.L. Weissman, The Long-Term Repopulating Subset of Hematopoietic Stem-Cells Is Deterministic and Isolatable by Phenotype. Immunity, 1994. 1(8): p. 661-673.
5. Baum, C.M., et al., Isolation of a Candidate Human Hematopoietic Stem-Cell Population. Proceedings of the National Academy of Sciences of the United States of America, 1992. 89(7): p. 2804-2808.
6. Osawa, M., et al., Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science, 1996. 273(5272): p. 242-245.
7. Clarke, M.F. and M. Fuller, Stem cells and cancer: Two faces of eve. Cell, 2006. 124(6): p. 1111-1115.
8. Dalerba, P., R.W. Cho, and M.F. Clarke, Cancer stem cells: Models and concepts, in Annual Review of Medicine. 2007. p. 267-284.
9. http://www.nature.com/ng/journal/v41/n11/fig_tab/ng1109-1164_F1.html.
10. Pardal, R., M.F. Clarke, and S.J. Morrison, Applying the principles of stem-cell biology to cancer. Nature Reviews Cancer, 2003. 3(12): p. 895-902.
11. Bonnet, D. and J.E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 1997. 3(7): p. 730-737.
12. Spira, A. and D.S. Ettinger, Multidisciplinary management of lung cancer - Reply. New England Journal of Medicine, 2004. 350(19): p. 2009-2010.
13. Hsu, H.S., et al., Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSM2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clinical Cancer Research, 2005. 11(15): p. 5410-5416.
14. Bernstein, E.D., S.M. Herbert, and N.H. Hanna, Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. Annals of Surgical Oncology, 2006. 13(3): p. 291-301.
15. Socinski, M.A. and J.A. Bogart, Limited-stage small-cell lung cancer: The current status of combined-modality therapy. Journal of Clinical Oncology, 2007. 25(26): p. 4137-4145.
16. Chen, Y.-C., et al., Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells. Plos One, 2008. 3(7).
17. Lam, W.K. and D.N. Watkins, Lung cancer: Future directions. Respirology, 2007. 12(4): p. 471-477.
18. Al-Hajj, M., et al., Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003. 100(7): p. 3983-3988.
19. Jemal, A., et al., Cancer statistics, 2006. Ca-a Cancer Journal for Clinicians, 2006. 56(2): p. 106-130.
20. Ricci-Vitiani, L., et al., Identification and expansion of human colon-cancer-initiating cells. Nature, 2007. 445(7123): p. 111-115.
21. Goodell, M.A., et al., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Journal of Experimental Medicine, 1996. 183(4): p. 1797-1806.
22. Chiasson, B.J., et al., Adult mammalian forebrain ependymal and subependymal cells demonstrate proliferative potential, but only subependymal cells have neural stem cell characteristics. Journal of Neuroscience, 1999. 19(11): p. 4462-4471.
23. Seaberg, R.M. and D. van der Kooy, Stem and progenitor cells: the premature desertion of rigorous definitions. Trends in Neurosciences, 2003. 26(3): p. 125-131.
24. Vermeulen, L., et al., Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proceedings of the National Academy of Sciences of the United States of America, 2008. 105(36): p. 13427-13432.
25. Singh, S.K., et al., Identification of human brain tumour initiating cells. Nature, 2004. 432(7015): p. 396-401.
26. O′Brien, C.A., et al., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 2007. 445(7123): p. 106-110.
27. Ricci-Vitiani, L., et al., Colon cancer stem cells. Journal of Molecular Medicine-Jmm, 2009. 87(11): p. 1097-1104.
28. Todaro, M., et al., Colon Cancer Stem Cells: Promise of Targeted Therapy. Gastroenterology, 2010. 138(6): p. 2151-2162.
29. Papailiou, J., et al., Stem cells in colon cancer. A new era in cancer theory begins. International Journal of Colorectal Disease, 2011. 26(1): p. 1-11.
30. Yin, A.H., et al., AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood, 1997. 90(12): p. 5002-5012.
31. Hilbe, W., et al., CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. Journal of Clinical Pathology, 2004. 57(9): p. 965-969.
32. Eramo, A., et al., Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 2008. 15(3): p. 504-514.
33. Barker, N., et al., Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature, 2007. 449(7165): p. 1003-U1.
34. Haegebarth, A. and H. Clevers, Wnt Signaling, Lgr5, and Stem Cells in the Intestine and Skin. American Journal of Pathology, 2009. 174(3): p. 715-721.
35. Walker, F., et al., LGR5 Is a Negative Regulator of Tumourigenicity, Antagonizes Wnt Signalling and Regulates Cell Adhesion in Colorectal Cancer Cell Lines. Plos One, 2011. 6(7).
36. Kaneko, Y., et al., Musashi1: An evolutionally conserved marker for CNS progenitor cells including neural stem cells. Developmental Neuroscience, 2000. 22(1-2): p. 139-153.
37. Booth, C. and C.S. Potten, Gut instincts: thoughts on intestinal epithelial stem cells. Journal of Clinical Investigation, 2000. 105(11): p. 1493-1499.
38. Nishimura, S., et al., Expression of Musashi-1 in human normal colon crypt cells - A possible stem cell marker of human colon epithelium. Digestive Diseases and Sciences, 2003. 48(8): p. 1523-1529.
39. Huang, E.H., et al., Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis. Cancer Research, 2009. 69(8): p. 3382-3389.
40. Klonisch, T., et al., Cancer stem cell markers in common cancers - therapeutic implications. Trends in Molecular Medicine, 2008. 14(10): p. 450-460.
41. Joyce, J.A. and J.W. Pollard, Microenvironmental regulation of metastasis. Nature Reviews Cancer, 2009. 9(4): p. 239-252.
42. Armstrong, T., et al., Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clinical Cancer Research, 2004. 10(21): p. 7427-7437.
43. Hurt, E.M., et al., Identification of Vitronectin as an Extrinsic Inducer of Cancer Stem Cell Differentiation and Tumor Formation. Stem Cells, 2010. 28(3): p. 390-398.
44. Dityatev, A. and M. Schachner, Extracellular matrix molecules and synaptic plasticity. Nature Reviews Neuroscience, 2003. 4(6): p. 456-468.
45. Wall, S.J., et al., Meeting report: Proteases, extracellular matrix, and cancer: an AACR Special Conference in Cancer Research. Cancer Res, 2003. 63(15): p. 4750-5.
46. Dasgupta, S., S. Srinidhi, and J.K. Vishwanatha, Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges. J Carcinog, 2012. 11: p. 4.
47. Giancotti, F.G. and E. Ruoslahti, Transduction - Integrin signaling. Science, 1999. 285(5430): p. 1028-1032.
48. Hood, J.D. and D.A. Cheresh, Role of integrins in cell invasion and migration. Nature Reviews Cancer, 2002. 2(2): p. 91-+.
49. Lee, J.W. and R. Juliano, Mitogenic signal transduction by integrin- and growth factor receptor-mediated pathways. Molecules and Cells, 2004. 17(2): p. 188-202.
50. Sethi, T., et al., Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine, 1999. 5(6): p. 662-668.
51. Damiano, J.S., et al., Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 1999. 93(5): p. 1658-1667.
52. Uhm, J.H., et al., Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clinical Cancer Research, 1999. 5(6): p. 1587-1594.
53. Aoudjit, F. and K. Vuori, Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract, 2012. 2012: p. 283181.
54. Jinka, R., et al., Alterations in Cell-Extracellular Matrix Interactions during Progression of Cancers. International Journal of Cell Biology, 2012. 2012: p. 1-8.
55. Weiss, R.E. and A.H. Reddi, Synthesis and localization of fibronectin during collagenous matrix-mesenchymal cell interaction and differentiation of cartilage and bone in vivo. Proc Natl Acad Sci U S A, 1980. 77(4): p. 2074-8.
56. Kim, S., et al., The effect of fibronectin-coated implant on canine osseointegration. J Periodontal Implant Sci, 2011. 41(5): p. 242-7.
57. Norton, P.A. and R.O. Hynes, In vitro splicing of fibronectin pre-mRNAs. Nucleic Acids Res, 1990. 18(14): p. 4089-97.
58. Han, S.W., F.R. Khuri, and J. Roman, Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Research, 2006. 66(1): p. 315-323.
59. http://en.wikipedia.org/wiki/Main_Page.
60. Preissner, K.T. and D. Seiffert, Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thrombosis Research, 1998. 89(1): p. 1-21.
61. Habermann, B.F. and D.A. Cheresh, Vitronectin and its receptors. Current Opinion in Cell Biology, 1993. 5(5): p. 864-868.
62. Di Lullo, G.A., et al., Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. Journal of Biological Chemistry, 2002. 277(6): p. 4223-4231.
63. Mollenhauer, J., I. Roether, and H.F. Kern, Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas, 1987. 2(1): p. 14-24.
64. http://themedicalbiochemistrypage.org/extracellularmatrix.html.
65. Kleinman, H.K. and G.R. Martin, Matrigel: Basement membrane matrix with biological activity. Seminars in Cancer Biology, 2005. 15(5): p. 378-386.
66. Higuchi, A., et al., Bioinert surface of pluronic-immobilized flask for preservation of hematopoietic stem cells. Biomacromolecules, 2006. 7(4): p. 1083-1089.
67. Higuchi, A., et al., Temperature-induced cell detachment on immobilized pluronic surface. Journal of Biomedical Materials Research Part A, 2006. 79A(2): p. 380-392.
68. Ungefroren, H., et al., Interaction of tumor cells with the microenvironment. Cell Communication and Signaling, 2011. 9.
69. Higuchi, A., et al., Preservation of hematopoietic stem and progenitor cells from umbilical cord blood stored in a surface derivatized with polymer nanosegments. Biomacromolecules, 2008. 9(2): p. 634-639.
70. Todaro, M., et al., Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell, 2007. 1(4): p. 389-402.
71. Ieta, K., et al., Biological and genetic characteristics of tumor-initiating cells in colon cancer. Annals of Surgical Oncology, 2008. 15(2): p. 638-648.
72. von dem Borne, A.E., et al., A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol, 1978. 39(2): p. 195-207.
73. Collins, A.T., et al., Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 2005. 65(23): p. 10946-10951.
74. Welte, Y., et al., Cancer stem cells in solid tumors: elusive or illusive? Cell Communication and Signaling, 2010. 8.
75. Bao, S.D., et al., Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research, 2006. 66(16): p. 7843-7848.
76. Bruno, S., et al., CD133(+) renal progenitor cells contribute to tumor angiogenesis. American Journal of Pathology, 2006. 169(6): p. 2223-2235.
77. Yoshikawa, R., et al., Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. British Journal of Cancer, 2008. 98(10): p. 1670-1674.
78. Zhu, L.Q., et al., Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature, 2009. 457(7229): p. 603-U114.
79. Shmelkov, S.V., et al., CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest, 2008. 118(6): p. 2111-20.
80. Yang, Z.F., et al., Identification of local and circulating cancer stem cells in human liver cancer. Hepatology, 2008. 47(3): p. 919-928.
81. Dittfeld, C., et al., CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. Radiotherapy and Oncology, 2010. 94(3): p. 375-383.
82. Gupta, P.B., C.L. Chaffer, and R.A. Weinberg, Cancer stem cells: mirage or reality? Nat Med, 2009. 15(9): p. 1010-2.
83. Lo, P.K., et al., CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene, 2012. 31(21): p. 2614-26.
84. Lee, H.C., et al., Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells. Drug Des Devel Ther, 2013. 7: p. 491-502.
85. Higuchi, A., et al., Biomimetic Cell Culture Proteins as Extracellular Matrices for Stem Cell Differentiation. Chemical Reviews, 2012. 112(8): p. 4507-4540.
86. Visvader, J.E. and G.J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer, 2008. 8(10): p. 755-68.
87. Kao, T.C., et al., Suppression of cancer-initiating cells and selection of adipose-derived stem cells cultured on biomaterials having specific nanosegments. J Biomed Mater Res B Appl Biomater, 2014. 102(3): p. 463-76.
|